AzTrials
AzTrials

Early Rheumatoid ArthritisPhase 3CONCERTONCT01185301

Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)

A Phase 3 study testing adalimumab and methotrexate in people with Early Rheumatoid Arthritis, run by AbbVie (prior sponsor, Abbott) at 68 sites in 10 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine the effects of different doses of methotrexate (MTX) when taken with adalimumab in subjects with early rheumatoid arthritis (RA). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Early Rheumatoid Arthritis
What is being tested?
adalimumab and methotrexate
Could I receive a placebo?
No, everyone receives an active treatment
How many people
395 participants
Where
68 sitesin 10 countries
Study dates
Oct 2010to Sep 2012
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male and female subjects at least 18 years of age
  • Subject has a diagnosis of Rheumatoid Arthritis (RA) as defined by either the 1987-revised American College of Rheumatology (ACR) classification criteria or the new ACR/ European League Against Rheumatism (EULAR) diagnostic criteria for RA 2010 and has a disease duration of less than 1 year from diagnosis by a licensed health care provider
  • Subject must meet the following criteria:
  • Disease Activity Score of C-reactive Protein (DAS28[CRP]) ≥ 3.2 (at the Baseline visit only)
  • At least 6 swollen joints out of 66 assessed (at the Screening and Baseline visits)
  • At least 8 tender joints out of 68 assessed (at the Screening and Baseline visits)
Show all 9Show fewer
  • C-reactive protein (CRP) ≥ 1.5 mg/dL (at the Screening visit only), or erythrocyte sedimentation rate (ESR) ≥ 28 mm/1h (at the Screening and Baseline visits)
  • Fulfill at least one of the following three criteria: Rheumatoid Factor (RF) positive, have at least 1 bony erosion, anti-cyclic citrullinated peptide (anti-CCP) antibody positive
  • Subject is judged to be in good health as determined by the Principal Investigator based upon the results of medical history, laboratory profile, physical examination, chest x-ray (CXR), and a 12-lead electrocardiogram (ECG) performed during Screening

Who cannot join

  • Subject has previous exposure to any systemic biologic therapy including adalimumab
  • Subject has been previously treated with greater than 1 disease modifying antirheumatic drugs (DMARDs) or with methotrexate (MTX)
  • Subject has undergone joint surgery within the preceding two months (at joints to be assessed within the study)
  • Subject has chronic arthritis diagnosed before age 17 years
  • History of invasive infection (e.g., listeriosis and histoplasmosis), chronic or active Hepatitis C infection, human immunodeficiency virus (HIV) infection, immunodeficiency syndrome, chronic recurring infections or active tuberculosis (TB)
  • Hepatitis B virus: hepatitis B surface antigen (HBs Ag) positive (+) or detected sensitivity on the hepatitis B virus DNA (HBV DNA) polymerase chain reaction (PCR) qualitative test
  • Infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to the Baseline Visit or oral anti-infectives within 14 days prior to the Baseline visit
  • Female subject who is pregnant or breast-feeding or considering becoming pregnant

Trial locations and contacts

68 sites in 10 countries.

68 sites in 10 countries

United States30 sites
  • Site Reference ID/Investigator# 44284

    Atlanta, Georgia, 30312

  • Site Reference ID/Investigator# 38971

    Charleston, South Carolina, 29406

  • Site Reference ID/Investigator# 40651

    Clifton, New Jersey, 07012

  • Site Reference ID/Investigator# 42202

    Columbus, Ohio, 43213

  • Site Reference ID/Investigator# 39672

    Covington, Louisiana, 70433

  • Site Reference ID/Investigator# 39643

    Dallas, Texas, 75231

  • Site Reference ID/Investigator# 45325

    Dallas, Texas, 75246

  • Site Reference ID/Investigator# 41423

    Duncansville, Pennsylvania, 16635

  • Site Reference ID/Investigator# 41422

    Freehold, New Jersey, 07728

  • Site Reference ID/Investigator# 38907

    Gainesville, Georgia, 30501

  • Site Reference ID/Investigator# 40463

    Greenville, North Carolina, 27834

  • Site Reference ID/Investigator# 38912

    Hemet, California, 92543

  • Site Reference ID/Investigator# 52042

    Houston, Texas, 77074

  • Site Reference ID/Investigator# 38973

    Huntsville, Alabama, 35801

  • Site Reference ID/Investigator# 39666

    Jackson, Tennessee, 38305

  • Site Reference ID/Investigator# 38909

    Jacksonville, Florida, 32209

  • Site Reference ID/Investigator# 38972

    Lawrenceville, Georgia, 30045

  • Site Reference ID/Investigator# 45323

    Little Rock, Arkansas, 72205

  • Site Reference ID/Investigator# 41962

    Mesa, Arizona, 85202

  • Site Reference ID/Investigator# 40422

    Miami, Florida, 33169

  • Site Reference ID/Investigator# 44282

    Norman, Oklahoma, 73069

  • Site Reference ID/Investigator# 42204

    Omaha, Nebraska, 68114

  • Site Reference ID/Investigator# 39260

    Phoenix, Arizona, 85031

  • Site Reference ID/Investigator# 39670

    Rock Island, Illinois, 61201

  • Site Reference ID/Investigator# 38910

    Sarasota, Florida, 34239

  • Site Reference ID/Investigator# 40602

    Seattle, Washington, 98101

  • Site Reference ID/Investigator# 42282

    Springfield, Illinois, 62704

  • Site Reference ID/Investigator# 41424

    The Bronx, New York, 10467

  • Site Reference ID/Investigator# 39673

    Victorville, California, 92395

  • Site Reference ID/Investigator# 38911

    Wichita, Kansas, 67203

Other trials in United States

Czechia6 sites
  • Site Reference ID/Investigator# 44937

    Brno, 63800

  • Site Reference ID/Investigator# 48962

    České Budějovice, 37021

  • Site Reference ID/Investigator# 44939

    Ostrava, 72200

  • Site Reference ID/Investigator# 44936

    Prague, 128 50

  • Site Reference ID/Investigator# 44938

    Uherské Hradiště, 686 01

  • Site Reference ID/Investigator# 48963

    Zlín, 76001

Other trials in Czechia

Germany5 sites
  • Site Reference ID/Investigator# 44941

    Berlin, 10117

  • Site Reference ID/Investigator# 44945

    Buch, 13125

  • Site Reference ID/Investigator# 44942

    Munich, 80336

  • Site Reference ID/Investigator# 44944

    Ratingen, 40882

  • Site Reference ID/Investigator# 44943

    Zerbst, 39261

Other trials in Germany

Poland5 sites
  • Site Reference ID/Investigator# 44946

    Bydgoszcz, 85168

  • Site Reference ID/Investigator# 44982

    Lodz, 90-242

  • Site Reference ID/Investigator# 46584

    Torun, 87-100

  • Site Reference ID/Investigator# 44984

    Warsaw, 02-118

  • Site Reference ID/Investigator# 44983

    Warsaw, 02-256

Other trials in Poland

Puerto Rico5 sites
  • Site Reference ID/Investigator# 38975

    Caguas, 00725

  • Site Reference ID/Investigator# 40122

    San Juan, 00906-6312

  • Site Reference ID/Investigator# 39693

    San Juan, 00936-5067

  • Site Reference ID/Investigator# 38916

    San Juan, 00936-8344

  • Site Reference ID/Investigator# 39692

    Vega Baja, 00693

Other trials in Puerto Rico

Argentina4 sites
  • Site Reference ID/Investigator# 44924

    Buenos Aires, C1055AAF

  • Site Reference ID/Investigator# 44926

    Buenos Aires, C1425DTG

  • Site Reference ID/Investigator# 44925

    Rosario, Santa Fe, S2000PBJ

  • Site Reference ID/Investigator# 47302

    San Juan, J5402DIL

Other trials in Argentina

Belgium4 sites
  • Site Reference ID/Investigator# 44934

    Brussels, 1200

  • Site Reference ID/Investigator# 44935

    Genk, 3600

  • Site Reference ID/Investigator# 44933

    Gilly, 6060

  • Site Reference ID/Investigator# 44932

    Liège, 4000

Other trials in Belgium

Spain4 sites
  • Site Reference ID/Investigator# 44947

    A Coruña, 15006

  • Site Reference ID/Investigator# 44987

    Elche (Alicante), 03203

  • Site Reference ID/Investigator# 44948

    Oviedo (Asturias), 33006

  • Site Reference ID/Investigator# 47782

    Valencia, 46026

Other trials in Spain

Austria3 sites
  • Site Reference ID/Investigator# 44928

    Graz, 80360

  • Site Reference ID/Investigator# 44930

    Vienna, 1090

  • Site Reference ID/Investigator# 44927

    Vienna, 1100

Other trials in Austria

Canada2 sites
  • Site Reference ID/Investigator# 43783

    Edmonton, T5M 0H4

  • Site Reference ID/Investigator# 43782

    Winnipeg, R3A 1M3

Other trials in Canada

About this study

Official title: A Double-Blind, Randomized, Parallel-Arm, Multicenter Study to Determine the Dose Response of Methotrexate (MTX) in Combination Therapy With Adalimumab in Subjects With Early Rheumatoid Arthritis (CONCERTO)

The purpose of this study is to determine the effects of different doses of methotrexate (MTX) when taken with adalimumab in subjects with early rheumatoid arthritis (RA).

Keywords
Arthritis, Erosion, Humira, Adalimumab, Injection, Rheumatoid, Methotrexate
Medical subject headings
Arthritis, Rheumatoid, Arthritis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • adalimumabBiological

    Also called Humira

    Pre-filled syringe every other week

  • methotrexateDrug

    weekly oral capsule dosing

Study groups in NCT01185301
Study groupRoleWhat they receive
ADA + 2.5 mg MTXActive comparator2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks
Receives: Biological: adalimumab; Drug: methotrexate
ADA + 5 mg MTXActive comparator5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks
Receives: Biological: adalimumab; Drug: methotrexate
ADA + 10 mg MTXActive comparator10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks
Receives: Biological: adalimumab; Drug: methotrexate
ADA + 20 mg MTXActive comparatorMTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks
Receives: Biological: adalimumab; Drug: methotrexate

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants With 28-Joint Disease Activity Score of C-reactive Protein (DAS28[CRP]) Low Disease Activity at Week 26

    Percentage of participants achieving low disease activity as defined by a clinical response (DAS28[CRP] < 3.2). The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score >5.1 indicates high disease activity, a DAS28 score <3.2 indicates low disease activity, and a DAS28 score <2.6 indicates clinical remission.

    Measured: Week 26

Secondary outcomes (12)
  1. Percentage of Participants With DAS28(CRP) Remission at Week 26

    Disease remission was defined as a disease activity score, based on CRP, for 28 joints that was < 2.6 (DAS28[CRP] < 2.6). The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10.

    Measured: Week 26

  2. Percentage of Participants With American College of Rheumatology (ACR) 20 Criteria Response at Week 26

    Response, as defined by ACR 20 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters:

    • Physician global assessment of disease activity
    • Patient global assessment of disease activity
    • Patient assessment of pain
    • Disability Index of the Health Assessment Questionnaire
    • Acute phase reactant value (C-reactive protein).

    Measured: Baseline, Week 26

  3. Percentage of Participants With American College of Rheumatology (ACR) 50 Criteria Response at Week 26

    Response, as defined by ACR 50 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 50% improvement in tender joint count; ≥ 50% improvement in swollen joint count; and ≥ 50% improvement in at least 3 of the 5 following parameters:

    • Physician global assessment of disease activity
    • Patient global assessment of disease activity
    • Patient assessment of pain
    • Disability Index of the Health Assessment Questionnaire
    • Acute phase reactant value (C-reactive protein).

    Measured: Baseline, Week 26

  4. Percentage of Participants With American College of Rheumatology (ACR) 70 Criteria Response at Week 26

    Response, as defined by ACR 70 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 70% improvement in tender joint count; ≥ 70% improvement in swollen joint count; and ≥ 70% improvement in at least 3 of the 5 following parameters:

    • Physician global assessment of disease activity
    • Patient global assessment of disease activity
    • Patient assessment of pain
    • Disability Index of the Health Assessment Questionnaire
    • Acute phase reactant value (C-reactive protein).

    Measured: Baseline, Week 26

  5. Percentage of Participants With American College of Rheumatology (ACR) 90 Criteria Response at Week 26

    Response, as defined by ACR 90 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 90% improvement in tender joint count; ≥ 90% improvement in swollen joint count; and ≥ 90% improvement in at least 3 of the 5 following parameters:

    • Physician global assessment of disease activity
    • Patient global assessment of disease activity
    • Patient assessment of pain
    • Disability Index of the Health Assessment Questionnaire
    • Acute phase reactant value (C-reactive protein).

    Measured: Baseline, Week 26

  6. Percentage of Participants With American College of Rheumatology (ACR) 100 Criteria Response at Week 26

    Response, as defined by ACR 100 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 100% improvement in tender joint count; ≥ 100% improvement in swollen joint count; and ≥ 100% improvement in at least 3 of the 5 following parameters:

    • Physician global assessment of disease activity
    • Patient global assessment of disease activity
    • Patient assessment of pain
    • Disability Index of the Health Assessment Questionnaire
    • Acute phase reactant value (C-reactive protein).

    Measured: Baseline, Week 26

  7. Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 26

    The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of < 0.5. Negative change from Baseline in the overall score indicates improvement.

    Measured: Baseline, Week 26

  8. Percentage of Participants With a Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) ≤ -0.22 at Week 26

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The minimal clinically important difference (MCID) defined for the HAQ-DI is a change from Baseline of ≥ 0.22. HAQ remission indicating normal physical function is defined by HAQ-DI score of < 0.5. Negative change from Baseline in the overall score indicates improvement.

    Measured: Baseline, Week 26

  9. Change From Baseline in Modified Total Sharp Score (mTSS) at Week 26

    The modified Total Sharp Score (mTSS) is a measure of change in joint health from digitized images of radiographs of hands and feet. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

    Measured: Baseline, Week 26

  10. Percentage of Participants With No Radiographic Progression at Week 26

    "No radiographic progression" was defined as a change from Baseline in modified Total Sharp Score (mTSS) at Week 26 of ≤ 0.5. mTSS is a measure of change in joint health from digitized images of radiographs of hands and feet. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

    Measured: Baseline, Week 26

  11. Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission at Week 26

    SDAI is a measure of disease activity derived as follows: SDAI = SJC28 + TJC28 + GH (cm) + PhGA (cm) + CRP (mg/dL), where TJC28 and SJC28 represent total tender joint count and total swollen joint count, respectively, based on 28 joints (including the left and right side of the body), GH = Patient's Global Assessment of Disease Activity, and PhGA = Physician's Global Assessment of Disease Activity (both measured on a visual analogue scale with a range of 0 [none] to 10 [severe]), and CRP is C-reactive protein measured in mg/dL. SDAI total score = 0 to 86. SDAI ≤ 3.3 indicates disease remission, > 3.4 to 11 = low disease activity, > 11 to 26 = moderate disease activity, and > 26 = high disease activity.

    Measured: Week 26

  12. Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Week 26

    CDAI is a measure of disease activity derived as follows: CDAI = SJC28 + TJC28 + GH (cm) + PhGA (cm) where TJC28 and SJC28 represent total tender joint count and total swollen joint count, respectively, based on 28 joints (including the left and right side of the body), GH = Patient's Global Assessment of Disease Activity, and PhGA = Physician's Global Assessment of Disease Activity (both measured on a visual analogue scale with a range of 0 [none] to 10 [severe]). CDAI total score = 0 to 76. CDAI ≤ 2.8 indicates disease remission, > 2.8 to 10 = low disease activity, > 10 to 22 = moderate disease activity, and > 22 = high disease activity.

    Measured: Week 26

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Aug 2010 (estimated)
  2. Study startOct 2010
  3. Primary completionSep 2012
  4. Study completionSep 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
395 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01185301
Sponsor's protocol ID
M12-073
Other IDs
2010-019514-24
Acronym
CONCERTO
Status last verified
Sep 2013
First submitted
18 Aug 2010
Last updated
15 Nov 2013
Data monitoring committee
No

Publications

  • Goss SL, Klein CE, Jin Z, Locke CS, Rodila RC, Kupper H, Burmester GR, Awni WM. Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial. Clin Ther. 2018 Feb;40(2):309-319. doi: 10.1016/j.clinthera.2018.01.002.

    PubMed 29402521
  • Burmester GR, Kaeley GS, Kavanaugh AF, Gabay C, MacCarter DK, Nash P, Takeuchi T, Goss SL, Rodila R, Chen K, Kupper H, Kalabic J. Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab. RMD Open. 2017 Sep 17;3(2):e000465. doi: 10.1136/rmdopen-2017-000465. eCollection 2017.

    PubMed 28955494
  • Burmester GR, Landewe R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Feb;76(2):414-417. doi: 10.1136/annrheumdis-2016-209322. Epub 2016 Jun 23.

    PubMed 27338778

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing adalimumab and methotrexate in people with Early Rheumatoid Arthritis, run by AbbVie (prior sponsor, Abbott) at 68 sites in 10 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Nov 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 68 sites in United States, Czechia, Germany, Poland, Puerto Rico and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 15 Nov 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants With 28-Joint Disease Activity Score of C-reactive Protein (DAS28[CRP]) Low Disease Activity at Week 26 (time frame: Week 26). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01185301, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Nov 2013; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in